Zobrazeno 1 - 10
of 261
pro vyhledávání: '"Jerome B, Zeldis"'
Autor:
Selvakumar Subbian, Liana Tsenova, Jennifer Holloway, Blas Peixoto, Paul O'Brien, Véronique Dartois, Vikram Khetani, Jerome B. Zeldis, Gilla Kaplan
Publikováno v:
EBioMedicine, Vol 4, Iss C, Pp 104-114 (2016)
Objectives: Adjunctive host-directed therapy is emerging as a new potential approach to improve the outcome of conventional antimicrobial treatment for tuberculosis (TB). We tested the ability of a phosphodiesterase-4 inhibitor (PDE4i) CC-11050, co-a
Externí odkaz:
https://doaj.org/article/f6df5ed8b2964f1d815adcb0d25e25ee
Autor:
Vaishali Sanchorawala, Jaymin M. Patel, J. Mark Sloan, Anthony C. Shelton, Jerome B. Zeldis, David C. Seldin
Publikováno v:
Haematologica, Vol 98, Iss 5 (2013)
We report results of a phase II trial of combination of melphalan, lenalidomide, and dexamethasone for the treatment of immunoglobulin light chain (AL) amyloidosis. The primary objectives were tolerability and hematologic response rate; secondary obj
Externí odkaz:
https://doaj.org/article/80a6e1eae436479d91421df5ac32ed3c
Autor:
Tamara Kreiss, Sreedhar R. Tummalapalli, Agnieszka Nawrocka Chojnowski, Vikram Khetani, David P. Rotella, Stacie S. Canan, Jerome B. Zeldis, Deborah Mortensen, Rohit Bhat, John J. Siekierka, Monika Prorok, Natalie Anne Hawryluk, Ronald Goldberg
Publikováno v:
ACS Medicinal Chemistry Letters. 9:210-214
[Image: see text] Lymphatic filariasis infects over 120 million people worldwide and can lead to significant disfigurement and disease. Resistance is emerging with current treatments, and these therapies have dose limiting adverse events; consequentl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5af9693035d8897650bb94bf8c5cdc5d
https://doi.org/10.1021/acsmedchemlett.7b00477
https://doi.org/10.1021/acsmedchemlett.7b00477
Autor:
Jean-Luc Harousseau, Meletios A. Dimopoulos, Michael Wang, Alessandro Corso, Christine Chen, Michel Attal, Andrew Spencer, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert D. Knight, Donna M. Weber
Publikováno v:
Haematologica, Vol 95, Iss 10 (2010)
Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the out
Externí odkaz:
https://doaj.org/article/ebc7dccaccd24460a4e984685c397be8
Autor:
Linda Mileshkin, Dirk Honemann, Peter Gambell, Melanie Trivett, Yoshihiro Hayakawa, Mark Smyth, Victoria Beshay, David Ritchie, Paul Simmons, Alvin D. Milner, Jerome B. Zeldis, H. Miles Prince
Publikováno v:
Haematologica, Vol 92, Iss 8 (2007)
Background and Objectives In vitro studies suggest that thalidomide has an immunoregulatory role and alters the marrow microenvironment. We assessed laboratory and clinical parameters in patients with myeloma treated with thalidomide as potential pro
Externí odkaz:
https://doaj.org/article/489d6378fcd649bfb77af26e4f6029ff
Autor:
Jerome B. Zeldis, Weifang Ling, Gunnar F. Kaufmann, Kristina Tess, Kevin Jhun, Shuyang He, Kathy Karasiewicz, Robert J. Hariri, Henry Ji, Xiaokui Zhang
Publikováno v:
Cancer Research. 80:2188-2188
Introduction: Celularity, Inc. is developing a CD19 CAR-T cell therapy using an allogeneic platform derived from postpartum human placental cells. To augment the CD19 CAR expression and activity of Placental-derived T (P-T) cells, we have evaluated t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8caac4b952cc1e0bfc04ff31ddbdfb3
https://doi.org/10.1158/1538-7445.am2020-2188
https://doi.org/10.1158/1538-7445.am2020-2188
Autor:
Mats Ökvist, Grete Stjernholm, Maja A. Sommerfelt, Angus G. Dalgleish, Gunnar M Hoddevik, Birger Sørensen, Robert R. Redfield, Arnt-Ove Hovden, Peter Lawrence Smith, Øyvind Jelmert, Jerome B. Zeldis, Valentina Ustina
Publikováno v:
AIDS Research and Human Retroviruses. 33:558-566
Antibodies to the carboxy-terminal constant (C5) region 5 of the HIV-1 envelope glycoprotein gp120 have previously been associated with slow disease progression. This is one of the regions on gp120 that interact with the transmembrane glycoprotein, g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07c19b9cb1bbf081fe60904951c63c98
https://doi.org/10.1089/aid.2016.0184
https://doi.org/10.1089/aid.2016.0184
Autor:
Nancy A. Brandenburg, Paul Sheehan, John Freeman, Robert Bwire, Florence Houn, Jerome B. Zeldis
Publikováno v:
Drug Safety
Introduction The effectiveness of patient education activities conducted within the lenalidomide and thalidomide risk evaluation and mitigation strategies (REMS) programs was evaluated by measuring understanding of serious risk and safe-use messages.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d82876361508671e6e68265c334f7a8
https://doi.org/10.1007/s40264-016-0501-2
https://doi.org/10.1007/s40264-016-0501-2